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Abstract
Cigarette smoke-induced release of pro-inflammatory cytokines including interleukin-8 (IL-8) from inflammatory as well as
structural cells in the airways, including airway smooth muscle (ASM) cells, may contribute to the development of chronic
obstructive pulmonary disease (COPD). Despite the wide use of pharmacological treatment aimed at increasing intracellular
levels of the endogenous suppressor cyclic AMP (cAMP), little is known about its exact mechanism of action. We report here
that next to the b2-agonist fenoterol, direct and specific activation of either exchange protein directly activated by cAMP
(Epac) or protein kinase A (PKA) reduced cigarette smoke extract (CSE)-induced IL-8 mRNA expression and protein release by
human ASM cells. CSE-induced IkBa-degradation and p65 nuclear translocation, processes that were primarily reversed by
Epac activation. Further, CSE increased extracellular signal-regulated kinase (ERK) phosphorylation, which was selectively
reduced by PKA activation. CSE decreased Epac1 expression, but did not affect Epac2 and PKA expression. Importantly,
Epac1 expression was also reduced in lung tissue from COPD patients. In conclusion, Epac and PKA decrease CSE-induced IL-
8 release by human ASM cells via inhibition of NF-kB and ERK, respectively, pointing at these cAMP effectors as potential
targets for anti-inflammatory therapy in COPD. However, cigarette smoke exposure may reduce anti-inflammatory effects of
cAMP elevating agents via down-regulation of Epac1.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic
inflammatory disorder characterized by infiltration of inflamma-
tory cells into the airways. Cigarette smoke-induced inflammation
is a main player in the development of COPD [1]. Neutrophils are
an important component of the inflammation as they release
inflammatory mediators and proteinases, which are believed to
play a role in the pathogenesis of COPD [2,3]. Moreover,
neutrophil number has been associated with COPD severity [2,4]
and exacerbation frequency [5]. Interleukin-8 (IL-8) is a potent
neutrophil chemoattractant and activator [2]; its abundance
correlates with neutrophil counts in COPD [6], and is increased
in sputum [7], in broncho-alveolar lavage fluid [8] and in the
bronchiolar epithelium from COPD patients [9]. Furthermore,
mRNA expression of IL-8 in bronchial biopsies correlates with
COPD progression [10]. Cigarette smoke induces release of IL-8
from inflammatory cells [11,12] and structural cells in the lung
[9,13], including airway smooth muscle (ASM) cells [14,15]. In
vitro, IL-8 release by cigarette smoke extract (CSE) involves
activation of nuclear factor kappa B (NF-kB) [12,14] and
extracellular signal-regulated kinase (ERK) [11,14]. Activation of
NF-kB requires phosphorylation and degradation of IkBa and
subsequent nuclear translocation of the NF-kB subunit p65
[16,17], whereas ERK activation occurs via phosphorylation and
subsequent nuclear translocation [18].
Currently, the most effective intervention for COPD is smoking
cessation [19], but no preventive or curative pharmacological
treatment exists. Despite their immuno-suppressive effects in
asthmatics, corticosteroids do not exhibit significant anti-inflam-
matory properties in patients with COPD [20–22], partly due to
the different types of inflammation involved. COPD therapy is
primarily aimed on symptomatic treatment, which includes the use
of bronchodilator drugs such as inhaled b2-agonists that increase
intracellular cyclic adenosine monophosphate (cAMP) in ASM
[23]. Of note, b2-agonists can inhibit cytokine release in vitro [24–
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e3157426], but evidence of their anti-inflammatory effectiveness of b2-
agonists in vivo is lacking, which may be due to the b2-adrenergic
receptor desensitization in both airway inflammatory and
structural cells [27,28]. Hence, activation of post-b2-adrenergic
receptor mechanisms could be advantageous to maintain the
beneficial effects of b2-agonists without the risk of receptor
desensitization.
Among the structural cells in the airways, ASM cells represent a
promising therapeutic target in chronic obstructive lung disease,
due to their multifunctional behavior that subserves bronchocon-
striction, wound healing and local inflammation [29]. Moreover,
ASM release IL-8 [30] and express Gs protein-coupled b2-
adrenergic receptors that couple with the cAMP effectors [23]
protein kinase A (PKA) and exchange proteins activated by cAMP
(Epac). Recently, we have shown that PKA and Epac modulate
IL-8 release in ASM cells via an ERK-dependent mechanism [31].
Although the contribution of the different cAMP effectors was not
studied, cAMP elevation by the b2-agonist salmeterol inhibited
CSE-induced IL-8 release by human neutrophils [11]. We
investigate here the modulatory role of Epac and PKA in CSE-
induced IL-8 release by ASM cells and the underlying molecular
mechanisms. We report that Epac and PKA exert their anti-
inflammatory properties upon the inhibition of NF-kB and ERK,
respectively. We also demonstrate that CSE reduced specifically
Epac1 protein expression, both in vitro and in COPD patients.
Results
cAMP signalling attenuates CSE-induced IL-8 release
from human ASM cells
Stimulation of hTERT-ASM cells with 15% CSE for 24 hrs
significantly increased basal IL-8 release of approximately 7-fold
(Fig. 1A–C), without affecting cell viability (Fig. 1D).
The CSE-induced IL-8 release was almost fully inhibited by co-
treatment with the b2-agonist fenoterol (0.1 and 1 mM; P,0.001
both; Fig. 1A), in a concentration-dependent manner. To study
the role of individual cAMP effectors Epac and PKA in the
inhibition of CSE-induced release of IL-8, we applied the selective
PKA activator 6-Bnz-cAMP (100 and 500 mM) and the selective
Epac activator 8-pCPT-29-O-Me-cAMP (30 and 100 mM). Treat-
ment with 6-Bnz-cAMP concentration-dependently and fully
inhibited CSE-induced IL-8 release (P,0.001; Fig. 1C). Only
the highest concentration of 8-pCPT-29-O-Me-cAMP (100 mM)
inhibited IL-8 release, albeit to a lesser degree as compared to
activation of PKA (P,0.05; Fig. 1B). None of the stimuli
significantly altered basal IL-8 levels, in agreement with our
previous observations [31] (Fig. 1A–C). Treatment with 8-pCPT-
29-O-Me-cAMP (100 mM), 6-Bnz-cAMP (500 mM) and fenoterol
(1 mM) did not affect cell viability (Fig. 1D). Specific activation of
Epac or of PKA did not affect the protein expression of these
cAMP effectors either (not shown).
Figure1.Fenoterol,6-Bnz-cAMP and8-pPCT-29-O-Me-cAMP reduceCSE-inducedIL-8releasefromhumanASM cells.hTERTASMcells(A,
B and C) and human primary ASM cells (F) were stimulated with 15% CSE in the absence or presence of fenoterol (0.1 or 1 mM), 6-Bnz-cAMP (100 mMo r
500 mM) or 8-pCPT-29-O-Me-cAMP (30 or 100 mM) for 24 hrs. Basal IL-8 release was 109,4633,2 pg/ml in hTERT ASM cells and 7,564,7 in primary human
ASM cells. Cells stimulated with 15% CSE for 6 hrs showed an increase in IL-8 mRNA expression which was reduced by fenoterol (1 mM), 6-Bnz-cAMP
(500 mM) or 8-pCPT-29-O-Me-cAMP (100 mM) (E). CSE, Fenoterol, 6-Bnz-cAMP and 8-pPCT-29-O-Me-cAMP did not affect cell viability (D). Results are
represented as means 6 SEM of 6–22 separate experiments. Statistical analysis was performed by one-way ANOVA followed by a Newman-Keuls post-
hoc test.
***P,0.001,
**P,0.01 compared to basal control;
#P,0.05,
##P,0.01.
###P,0.001 compared to CSE-stimulated control.
doi:10.1371/journal.pone.0031574.g001
Anti-Inflammatory Role of cAMP Effectors in COPD
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31574Analysis of IL-8 mRNA expression in hTERT-ASM showed
that the effects on IL-8 release were reflected on the level of IL-8
gene transcription. Thus, the IL-8 mRNA expression was
increased 6 hrs after stimulation with CSE (P,0.001). Treatment
with 6-Bnz-cAMP (500 mM) and fenoterol (1 mM) significantly
reduced the CSE-induced IL-8 mRNA expression (P,0.001 both),
whereas a trend (P=0.08) towards a reduction by 8-pCPT-29-O-
Me-cAMP (100 mM) was observed (Fig. 1E).
Similar to the effects in the immortalized cells, treatment with
15% CSE significantly enhanced IL-8 release of approximately 9-
fold in primary human ASM cells (Fig. 1F). Co-stimulation with
fenoterol (1 mM), 6-Bnz-cAMP (500 mM) and 8-pCPT-29-O-Me-
cAMP (100 mM) also reduced CSE-induced IL-8 release from
primary human ASM cells (P,0.05, P,0.01), without affecting
basal IL-8 levels (Fig. 1F).
The specific effects of the two cAMP effectors Epac and PKA on
IL-8 release by hTERT-ASM cells were validated using different
experimental approaches. siRNA probes against Epac1 and Epac2
were used to silence Epac [31]. Efficiency of transfection was
evaluated by qPCR (Fig. 2A) and by western blot analysis (Fig. 2B).
The mRNA and protein expression of Epac1 and Epac2 were
both significantly down-regulated after co-transfection with Epac1
and Epac2 siRNA compared to control siRNA treatment (Fig. 2A–
B). Treatment with siRNA for either Epac1 or Epac2 only slightly
and non significantly reduced the inhibitory effect of 8-pCPT-29-
O-Me-cAMP on CSE-induced IL-8 release (not shown). However,
simultaneous knock-down of both Epac1 and Epac2 mRNA and
protein (Fig. 2C), effectively impaired the inhibitory effect of 8-
pCPT-29-O-Me-cAMP on CSE-induced IL-8 release from
hTERT-ASM cells by about 50% (P,0.001, Fig. 2C), leaving
the basal and CSE-induced IL-8 release unaffected (not shown). As
expected, the effect of the PKA activator 6-Bnz-cAMP was not
affected by the siRNA silencing of Epac1 and Epac2 (Fig. 2C). The
specificity of the cAMP analogs was confirmed by evaluation of the
phosphorylation of the PKA-specific substrate VASP (vasodilator-
activated phosphoprotein). Thus, PKA activation with 6-Bnz-
cAMP, but not Epac activation with 8-pCPT-29-O-Me-cAMP,
induced VASP phosphorylation, an effect that could be reduced
by the PKA inhibitor H89 (300 nM; Fig. 3A). Moreover, the
inhibitory effect of 6-Bnz-cAMP, but not 8-pCPT-29-O-Me-
cAMP, on CSE-induced IL-8 release was largely reduced by
H89 (P,0.001, Fig. 3B) and by the combination of specific PKA
inhibitors [32] Rp-8-Br-cAMP and Rp-cAMPS (500 mM, each
P,0.01, Fig. 3C). None of the inhibitors altered Epac-mediated
effects on CSE-induced IL-8 release (Fig. 3B–C).
Role of NF-kB in CSE-induced IL-8 release
NF-kB activation has been shown to be crucial for CSE-induced
IL-8 production [11,14]. In line, the IKK-2 inhibitor SC514
(50 mM) significantly reduced CSE-induced IL-8 release from
hTERT ASM cells by .50% (P,0.001) (not shown), confirming
the importance of the NF-kB pathway. Accordingly, treatment of
hTERT-ASM cells with CSE for 2 hrs increased nuclear staining
of the NF-kB subunit p65 (P,0.001, Fig. 4A–B), indicating
increased translocation of the transcriptionally active NF-kB
subunit from the cytosol to the nucleus. The Epac activator 8-
pCPT-29-O-Me-cAMP and the PKA activator 6-Bnz-cAMP did
not affect basal p65 cellular localization (Fig. 4A). Importantly,
p65 nuclear translocation by CSE was significantly inhibited by 8-
pCPT-29-O-Me-cAMP (P,0.001) (Fig. 4A–B). p65 nuclear
translocation was preceded by loss (degradation) of the NF-kB
inhibitory protein IkBa after 1 hr treatment with CSE (P,0.05,
Fig. 4C). This response was largely prevented by the Epac
activator (P,0.05 Fig. 4C), and only slightly upon PKA activation
by 6-Bnz-cAMP (Fig. 4C). Taken together, these findings indicate
that stabilization of the IkBa-p65 complex underlies the inhibitory
effect of Epac on NF-kB activation.
Role of ERK in CSE-induced IL-8 release
In line with previous studies from our group [14,33], CSE
induced a significant increase in ERK phosphorylation in
hTERT-ASM cells after 1 hr of stimulation (P,0.05, Fig. 5).
The importance of the ERK pathway was supported by the effect
of MEK inhibitor U0126 (3 mM), which reduced CSE-induced IL-
8 release by about 50% (P,0.001) (not shown). Importantly, the
CSE-induced ERK activation was completely normalized by the
PKA activator 6-Bnz-cAMP (P,0.05, Fig. 5) whereas activation of
Epac had no effect (Fig. 5). These findings clearly reveal
differential effects of PKA and Epac on CSE-induced ERK
activation.
Modulation of Epac expression by CSE
CSE down-regulated Epac1 mRNA and protein expression
(Fig. 6A & C; P,0.05 both) in hTERT-ASM cells after 24 hrs of
stimulation, leaving the mRNA and protein expression of Epac2
(Fig. 6A & C) and of the two subunits of PKA (Fig. 6B & D)
unaffected. In primary human ASM, CSE-induced down-regulation
of Epac1 mRNA was already apparent at 4 hrs after CSE
treatment (Fig. 6E) and remained down regulated after 24 hrs
(P,0.05 both). Similar to the findings in the hTERT-ASM cells,
the expression of Epac2 and PKA mRNA was not significantly
affected by CSE (Figs. 6F).
Expression patterns of Epac and PKA in lung tissue from
COPD patients
Given the effect of CSE on cultured human ASM cells, we also
evaluated the expression of Epac and PKA in lung tissue from
COPD patients and from asymptomatic smokers, whose charac-
teristics are described in Table 1. In line with the data in human
ASM cells (Fig. 6), no change was observed in the protein (Fig. 7A–
B) and mRNA expression (Figure S1) of Epac2 and PKA.
Although no differences were observed for Epac1 mRNA (Figure
S1), the expression of Epac1 protein was significantly lower in
COPD patients (P,0.05) (Fig. 7B).
Discussion
In this study, we show for the first time that the cAMP effectors
Epac and PKA exert a distinct inhibitory role on CSE-induced
release of IL-8 from human ASM cells. Thus, it was demonstrated
that Epac activation inhibits CSE-induced IL-8 release by blocking
NF-kB activation, whereas activation of PKA inhibits ERK
activation. Moreover, CSE significantly reduces Epac1 expression
in primary and immortalized human ASM cells, leaving Epac2
and PKA unaffected. Importantly, Epac1 protein abundance is
also significantly reduced in COPD patients, which may translate
our in vitro findings to a pathophysiological context.
Cigarette smoke contributes to the development of COPD by
inducing a chronic inflammation known to be associated with
irreversible damage of the airways and lung parenchyma
[1,34,35]. The observed pathogenetic potential of cigarette smoke
correlates in part with the increased release of the neutrophil
chemoattractant IL-8 by inflammatory and structural cells
[6,7,11–13] such as ASM cells [14,15]. Current objectives of
COPD therapy are to reduce episodes of airway obstruction and
improve airflow limitation as a means of improving quality of life.
Currently, no treatment effectively inhibits inflammation-driven
progressive decline in lung function [36], although recently, some
Anti-Inflammatory Role of cAMP Effectors in COPD
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[37]. Hence, there is a need for novel targets of anti-inflammatory
therapy in this disease.
Beside its beneficial acute bronchodilatory effects, cAMP also
exhibits in vitro anti-inflammatory properties in several cell types,
by inhibiting the release of cytokines by several cell types in the
airways [24–26]. This effect has typically been associated with
activation of PKA [26]. However, our prior data have shown that
next to PKA the novel cAMP effector Epac modulates bradykinin-
induced IL-8 release from human ASM cells [31]. Only few
studies have addressed the role of cAMP in CSE-induced IL-8
release [11,38], and the effects of both Epac and PKA on this
response have not been investigated at all. CSE-induced IL-8
release by human neutrophils is decreased by the b2-agonist
salmeterol [11], but it only reduces IL-8 release by human ASM
cells in the presence of fluticasone in studies using human ASM
Figure 2. Epac knock-down attenuates the inhibitory effect of 8-pCPT-29-O-Me-cAMP on CSE-induced IL-8 release. Epac1 and Epac2
mRNA and protein levels were analyzed after co-transfection with Epac1 and Epac2 siRNA or after transfection with control siRNA, resulting in a
significant downregulation of both Epac1 and 2 mRNA (A) and protein (B) compared to control siRNA. Transfected hTERT-ASM cells were stimulated
without (basal) or with 15% CSE in the absence or presence of either 500 mM 6-Bnz-cAMP or 100 mM 8-pCPT-29-O-Me-cAMP for 24 hrs (C). Data are
presented as means6SEM of 4–8 separate experiments. Statistical analysis was performed by one-way ANOVA followed by a Dunnett post-hoc test.
*P,0.05,
***P,0.001 compared to basal.
#P,0.05;
###P,0.001 compared to CSE.
{{P,0.01,
{{{P,0.001.
doi:10.1371/journal.pone.0031574.g002
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alone can reduce CSE-induced IL-8 release from human ASM
cells by itself, an effect that is mimicked by specific activation of
Epac and PKA. Differences in conditions for cell culture (i.e. high
and low passage tracheal vs bronchial primary ASM cells) and
treatment (salmeterol vs fenoterol and incubation time) could
account for the different effects observed. Importantly, our current
study definitively demonstrates the capacity for both Epac and
PKA to regulate CSE-induced inflammatory cytokine release in
immortalized and primary human ASM cells.
Epac and PKA appear to have similar effects with regard to
ASM synthetic, proliferative and contractile capacities [31,39,40].
As no cross-inhibition of both cAMP effectors was observed, we
can exclude a main contribution of cooperation between Epac and
PKA in our findings. Interestingly, our results indicate that Epac
and PKA exert their inhibitory effects towards CSE-induced IL-8
release via distinct signalling routes at the transcriptional level (as
shown by induction of IL-8 mRNA). It has been shown that CSE
activates both NF-kB and ERK to increase IL-8 release
[11,12,14]. In the current study, we demonstrate that activation
of Epac specifically inhibited CSE-induced NF-kB activation,
whereas activation of PKA specifically reduced ERK phosphor-
ylation. Thus, our study unravels novel distinct, but complemen-
tary, immunosuppressive mechanisms of Epac and PKA in human
ASM. Here we define NF-kB as the main target for the anti-
inflammatory role of Epac, whereas the anti-inflammatory effect of
PKA relies on ERK.
Despite the fact that both Epac and PKA are expressed in
cultured primary and immortalized human ASM cells [31,39] and
reduce CSE-induced IL-8 release, by using effective concentra-
tions of their selective activators we observed a stronger inhibitory
effect of PKA compared to Epac. The lower inhibitory efficacy of
the Epac activator 8-pCPT-29-O-Me-cAMP towards CSE may
relate to the observed reduced Epac1 abundance after CSE
treatment. As specific inhibitors of Epac are currently not
available, we tested the effects of Epac1 and 2 co-silencing on
CSE-induced IL-8 release by using the siRNA technique. This
technique reduced Epac mRNA and protein levels, in agreement
with our previous data [31]. Such a diminishment of Epac
expression resulted in a similar reduction of the anti-inflammatory
effects of Epac activation. This demonstrates that both isoforms of
Epac are implicated in the reduction of CSE-induced IL-8 release.
Importantly, we translated our findings to a pathophysiological
setting showing reduced Epac1 expression in lung homogenates
from COPD patients. Interestingly, our data indicate that Epac1
down-regulation is not solely related to acute smoking as it persists
after smoking cessation in COPD patients. Our data point at post-
translational modification of Epac1, as Epac1 mRNA levels in
COPD patients did not differ from the mRNA levels in the control
subjects. Lung damage and chronic inflammation by cigarette
smoke-induced oxidative stress caused irreversible alterations in
protein structure [41]. Such alterations might play a role in the
down-regulation of Epac1 protein in COPD patients. Reduced
expression of Epac1 has previously been shown in human lung
fibroblasts by the action of the COPD-associated pro-fibrotic
factor transforming growth factor-b [42].
These findings might have important clinical implications
towards a better understanding of COPD pathogenesis and the
improvement of its pharmacological treatment. Indeed, despite its
anti-inflammatory effects in vitro, clinical studies only show modest
beneficial effects of b2-agonists in the treatment of airway
inflammation [43,44]. Such a discrepancy has been assigned to
variable b2-adrenergic receptor abundance or its potential
polymorphisms [45] and additionally to alterations of b2-
adrenergic receptor signalling by homologous or heterologous
desensitization in both inflammatory and structural cells in the
airways [28,46,47]. As a potential effector in cAMP-driven and b2-
adrenergic receptor-induced signalling and a newly discovered
inhibitor of NF-kB-dependent inflammatory response, Epac1
down-regulation by cigarette smoke may provide an additional
Figure 3. Inhibition of PKA attenuates the effect of 6-Bnz-cAMP
on CSE-induced IL-8 release. Phosphorylation of VASP in hTERT-
ASM cells treated with 100 mM 8-pCPT-29-O-Me-cAMP or 500 mM 6-Bnz-
cAMP in the absence or presence of the PKA inhibitor H89 (300 nM) was
analysed by using an antibody, which recognizes both the phosphor-
ylated VASP (phospho-VASP) and the non phosphorylated VASP (VASP)
(A). VASP was normalized to GAPDH. Representative immunoblots of 3
experiments are shown. hTERT-ASM were pre-treated without (white
bars) or with (black bars) 300 nM H89 (B) or 500 mM of both Rp-8-Br-
cAMPS and Rp-cAMPS (C) for 30 min before stimulation with 15% CSE,
100 mM 8-pCPT-29-O-Me-cAMP, 500 mM 6-Bnz-cAMP or their combina-
tions. Data are presented as means6SEM of 3–9 separate experiments.
Statistical analysis was performed by one-way ANOVA followed by a
Newman-Keuls post-hoc test.
***P,0.001 compared to basal control.
#P,0.05,
###P,0.001 compared to CSE.
{P,0.05,
{{{P,0.001.
doi:10.1371/journal.pone.0031574.g003
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agonists in the treatment of COPD.
In conclusion, Epac and PKA inhibit CSE-induced IL-8 release
by human ASM by preventing the activation of NF-kB and ERK,
respectively. Thesefindings indicatethat EpacandPKAmighthave
potential as targets for anti-inflammatory therapy in COPD.
Moreover, CSE-induced reduction in Epac1 expression might
point to a divergent contribution of cAMP effectors in mediating
immunosuppressive effects of current drug therapies. Hence,
studying the mechanisms by which cigarette smoke exposure drives
Epac1 down-regulation could unveil alternative ways for interven-
tion, as targeting specific cAMP effectors could allow a more
effective controlof cAMP signalling driven by Gs-coupled receptors.
Methods
Human lung tissue
Human lung tissue was collected from COPD patients and
asymptomatic smokers, the latter as a control group (Table 1).
Classification of COPD severity was based on the Global Initiative
Figure 5. 6-Bnz-cAMP prevents CSE-induced ERK phosphorylation. hTERT-ASM cells were lysed after being stimulated with 15% CSE,
100 mM 8-pCPT-29-O-Me-cAMP, 500 mM 6-Bnz-cAMP or their combinations for 1 hr followed by Western blot analysis of phospho-ERK (p-ERK). Total
ERK (ERK) was used as a loading control. Representative immunoblots of p-ERK and ERK are shown. Data are presented as means6SEM of 7–8
separate experiments. Statistical analysis was performed by one-way ANOVA followed by a Dunnett post-hoc test.
*P,0.05 compared to basal
control.
#P,0.05 compared to CSE.
doi:10.1371/journal.pone.0031574.g005
Figure 4. 8-pCPT-29-O-Me-cAMP prevents CSE-induced breakdown of IkBa and p65 nuclear translocation. p65 nuclear translocation was
determined by immunofluorescence using p65 antibodies on hTERT-ASM cells stimulated without (control) or with 15% CSE for 2 hrs, alone or in
combination with 100 mM 8-pCPT-29-O-Me-cAMP or 500 mM 6-Bnz-cAMP. Representative results of 3 separate experiments are shown (A) with the
quantification of p65 nuclear staining (B). hTERT-ASM cells were treated with 15% CSE, 100 mM 8-pCPT-29-O-Me-cAMP, 500 mM 6-Bnz-cAMP or their
combinations for 1 hr. Cells were lysed and IkBa levels were determined by Western blot analysis (C). Bands were normalized to GAPDH. Representative
immunoblotsofIkBa andGAPDHareshown.Dataarepresentedas means6SEMof6–7separateexperiments.Statisticalanalysiswasperformedbyone-
way ANOVA followed by a Dunnett post-hoc test.
*P,0.05,
***P,0.001 compared to basal control.
#P,0.05,
###P,0.001 compared to CSE.
doi:10.1371/journal.pone.0031574.g004
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Tissue from the control group and from GOLD stage II patients
was derived from noninvolved lung tissue of patients undergoing
resective surgery for pulmonary carcinoma; the control group had
no airway obstruction or chronic airway symptoms, such as cough
and sputum production. Tissue from GOLD stage IV patients was
collected from subjects undergoing surgery for lung transplanta-
tion. The COPD-patients did not have clinical signs of chronic
bronchitis and were not suffering from alpha-1-antitrypsin
deficiency. The clinical characteristics of the patients are given
in Table 1. The study protocol was consistent with the Research
Code of the University Medical Center Groningen (http://www.
rug.nl/umcg/onderzoek/researchcode/index) and national ethi-
cal and professional guidelines (‘‘Code of conduct; Dutch
federation of biomedical scientific societies’’; htttp://www.federa.
org).
Cigarette smoke extract
Cigarette smoke extract was prepared as previously described
[33]. Briefly, 2 research cigarettes (University of Kentucky 2R4F;
filters removed) were combusted using a peristaltic pump (Watson
Marlow 323 E/D, Rotterdam, The Netherlands) and passing the
smoke through 25 ml of FBS-free DMEM supplemented with
antibiotics at a rate of 5 minutes/cigarette. The solution obtained
is referred to as 100% strength and was then diluted in FBS-free
DMEM+antibiotics to obtain a 15% working solution.
Cell culture
Human bronchial smooth muscle cell lines, immortalized by
stable ectopic expression of human telomerase reverse transcrip-
tase enzyme (hTERT-ASM), passages 1–30 were used. All
procedures were approved by the human Research Ethics Board
of the University of Manitoba [48]. Primary human ASM cells
were isolated from human tracheal sections from anonymized lung
transplantation donors (obtained from the Department of
Cardiothoracic Surgery, University Medical Center Groningen)
as previously described [39]. Passages 1–5 were used. Prior to the
experiments, cells were growth arrested overnight and treated with
fenoterol, 8-pCPT-29-O-Me-cAMP or 6-Bnz-cAMP for 20 min
before stimulation with CSE. The PKA inhibitors (H89, Rp-8-Br-
cAMPS plus Rp-cAMPS), the MEK inhibitor U0126 and the
IKK-2 inhibitor SC514 were added 30 min before the other
stimuli [40]. An Alamar blue assay was used to determine cell
viability as described previously [31].
IL-8 assay
24 hrs after stimulation of ASM cells with CSE, culture medium
was collected for the determination of IL-8 concentrations by
ELISA according to the manufacturer’s instructions (Sanquin, the
Netherlands), as previously described [31].
Silencing of Epac1 and Epac2 expression
Epac1 and Epac2 knock-down was achieved by transfection of
hTERT-ASM cells (90% confluency) with 200 pmol of siRNA
(Table S1). ON-TARGET plus Non-targeting Pool (D-001810-10-
20) was used as a negative control (control siRNA). Lipofectamine
2000 (1 mg/ml) was used as a vehicle. 6 hrs after transfection, cells
were washed. The day after, cells were seeded in 24 wells plates
and serum-deprived overnight. 24 hrs after stimulation with CSE
in the absence or presence of 8-pCPT-29-O-Me-cAMP or 6-Bnz-
cAMP, supernatants were collected for analysis of IL-8 levels.
Furthermore, transfected cells were lysed for analysis of Epac1 and
Epac2 protein or mRNA.
Western analysis
Cell lysates were prepared and subjected to protein determina-
tion using a Pierce BSA protein assay (Thermo Scientific,
Rockford, IL, USA). Similar protein amounts were loaded on a
SDS-Page gel (8–15%) for electrophoresis and transferred to a
nitrocellulose membrane. Incubation with the specific primary and
secondary antibodies was performed overnight (Table S2). After
the addition of western lighting plus-ECL, determination of
protein bands was achieved using the G-BOX iChemi (Syngene,
Cambridge, UK). Bands were normalized to GAPDH, b-actin or
ERK, depending on the protein under investigation.
mRNA isolation and RT-PCR
mRNA from cultured human ASM cells was extracted by using
a Nucleospin RNA II kit (Machery Nagel, Du ¨ren, Germany) and
quantified using spectrophotometry (Nanodrop, ThermoScientific,
Wilmington, USA). 1 mg of mRNA was converted in cDNA by
reverse transcriptase using Promega tools (Madison, WI, USA).
cDNA was subjected to real-time PCR (RT-PCR) using a
MyiQ
TM Single-Color detection system (Bio-Rad Laboratories
Inc. Life Science Group, Hercules, CA, USA) and specific primers
(Table S3). The amount of target gene was normalized to
ribosomal subunit 18 S (designated as DCT). Relative differences
were determined using the equation 2
2(DDCt). When necessary, a
1.2% gel was used to separate the RT-PCR products.
Figure 6. Epac1 is down-regulated by CSE. hTERT-ASM or primary ASM cells were treated for 4 and 24 hrs with 15% CSE. Then, cells were lysed
for protein and mRNA determination. mRNA (A) and protein expression (C) of Epac1 was significant down regulated after exposure to CSE, while
Epac2 was unaffected in hTERT cells. Same results were obtained in primary cells (E) Catalytic (PKA-C) and regulatory type II (PKA-RII) subunits of PKA
mRNA (B & F) and protein (D) expression were not affected by CSE exposure in hTERT cells and in primary ASM cells. Protein expression of Epac1 and
Epac2 (C) and PKA-C PKA-RII (D) were normalized to b-actin (for Epac) and GAPDH (for PKA). mRNA expression was normalized to 18 S. Data represent
mean6SEM of 3–5 independent experiments. Statistical analysis was performed by one-way ANOVA followed by a Newman-Keuls post-hoc test.
*P,0.05 compared to time point 0 hrs.
doi:10.1371/journal.pone.0031574.g006
Table 1. Characteristics of the study subjects.
Control COPD
Number of subjects 92 0
Age (years) 62 (46–78) 60.5 (44–81)
Male/female 3/6 12/8
Ex-smoker/current smoker 7/2 16/4
Pack years 30.0 (3.0–52.5) 31.5 (8.5–65.0)
FEV1% predicted 96.9 (71.9–134.0) 37.8 (14.0–75.8)
***
FEV1/FVC % 72.7 (70.6–85.3) 43.7 (19.2–71.1)
***
All values except number of subjects, gender and smoking status are expressed
as median values with minimum and maximum range in parentheses. Ex-
smoker: stopped smoking for at least one year. FEV1% predicted: forced
expiratory volume in 1 second as percentage of predicted value. FVC: forced
vital capacity.
***P,0.001 compared to control group.
doi:10.1371/journal.pone.0031574.t001
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immunoblotting. Equal protein loading was verified by the analysis of b-actin. Responses were quantified by densitometry and normalized to the
expression of b-actin. Data are derived from 9 controls and 15–19 COPD patients. Median of each group is indicated by -----. *P,0.05. Statistical
differences between control and COPD were determined by non-parametric Mann-Whitney test.
doi:10.1371/journal.pone.0031574.g007
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10.000 cells per well were plated in coverslips and serum
deprived for 24 hrs before stimulation. Cells were fixed by
addition of 3% paraformaldehyde (PFA) for 15 min, followed by
incubation in 3% PFA plus 0.3% Triton X-100 for 5 min. After
blocking, cells were incubated overnight with p65 antibody (Santa
Cruz, CA, USA, dilution 1:20) and donkey-anti rabbit FITC
(dilution: 1:50) was added. Nuclei were stained with a Hoechst
staining (1:10000). After this, coverslips were mounted using
ProLong Gold antifade reagent and analyzed using an Olympus
AX70 microscope equipped with digital image capture system
(ColorView Soft System with Olympus U CMAD2 lens).
Materials
6-Bnz-cAMP and 8-pCPT-29-O-Me-cAMP and the PKA
inhibitors Rp-cAMPS and Rp-8-Br-cAMPS were purchased from
BIOLOG Life Science Institute (Bremen, Germany). Fenoterol
was obtained from Boehringer Ingelheim (Ingelheim, Germany).
Protease inhibitors, albumin bovine serum, Triton X-100, H89
were from Sigma-Aldrich (St-Louis, MO, USA). Cell medium
components were from GIBCO-BRL Life Technologies (Paisley,
UK). Donkey serum and donkey anti-rabbit FITC fluorescent
antibody was obtained from Jackson Immuno Research (West
Grove, PA, USA). Hoechst nuclear staining, anti-fade solution,
lipofectamine 2000 (1 mg/ml) and Alamar Blue were purchased
from InVitrogen (Carlsbad, CA, USA) as well as the PCR primers.
ECL solution for western blot detection was purchased from
PerkinElmer Inc. (Waltman, MA, USA). siRNA probes were
obtained from Dharmacon Inc. (Lafayette, CO, USA). U0126 was
from Tocris Cookson Inc. (Bristol, UK). SC514 was obtained from
Calbiochem (Amsterdam, The Netherlands).
Statistical analysis
For cell culture experiments with multiple comparisons results
are expressed as mean6SEM of separate experiments and one-
way ANOVA followed by the indicated post hoc tests, was
performed.
For data derived from COPD and control subjects, values
represent medians (range between parenthesis) and a non-
parametric Mann Whitney test was used to evaluate differences.
P values,0.05 were considered to be statistically significant.
Supporting Information
Figure S1 Epac and PKA mRNA expression in COPD patients.
Expression of PKA-C and PKA-RII (A) and Epac1 and Epac2 (B)
was evaluated by qRT-PCR. Values were relative to 18 S values.
Data are derived from 9 controls and 15–19 COPD patients.
Median of each group is indicated by -----. Statistical differences
between control and COPD were determined by non-parametric
Mann-Whitney test. No statistical differences were found.
(TIF)
Table S1 Sequences of siRNA probes against Epac1 and Epac2.
(DOCX)
Table S2 List of antibodies used in western analysis.
(DOCX)
Table S3 Primers used for RT-PCR.
(DOCX)
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